

# Subject Index

- active treatments: assignment mechanisms and, 33–38, 41; basics of, 4, 8, 11, 13, 16–17, 19; classical randomized experiments and, 47–50, 52; Fisher exact p-values and, 59, 62, 64; instrumental variables analysis and, 514, 517, 523–525, 528, 530, 536, 539–540, 542, 569; labor market and, 246; model-based analysis and, 169–170, 569; Neyman’s repeated sampling approach and, 83, 87, 105; pairwise randomized experiments and, 220–221, 225, 227; propensity score and, 282, 307; regression analysis and, 131; sampling variances and, 446; sensitivity analysis and, 500; stratified randomized experiments and, 187, 190, 211; unconfoundedness and, 266, 479, 481, 485
- affine consistency, 434, 441–444
- AIDS, 12
- Aid to Families with Dependent Children (AFDC), 240
- always takers: instrumental variables analysis and, 545–546, 549–555, 562t, 563–565, 568–572, 574–579, 581, 583; model-based analysis and, 562t, 563–565, 568–572, 574–579, 581, 583
- Analysis of Variance (ANOVA), 298
- assignment mechanisms, xviii, 34, 589; *a priori* approach and, 33, 41; assumptions and, 16, 32–34, 36, 39, 42–43; attributes and, 33; balance and, 32, 42; basics of, 3, 7, 13–17, 20–21; before Neyman, 24; causal effects and, 31, 36, 42; causal estimands and, 34; classical randomized experiments and, 47–54; classification of, 31–44; completely randomized experiments and, 41; conditional independence assumption and, 43; control units and, 35, 41–42; covariates and, 20, 31–39, 42; design stage and, 32; drug treatment and, 34, 40; exclusion restrictions and, 42; Fisher exact p-values and, 58; general causal estimands and, 479–495; ignorable assignment and, 39; individualistic assignment and, 31, 37–39, 43, 259, 261–262, 316; instrumental variables analysis and, 43, 527, 567, 570; irregular, 20, 42–43; missingness and, 43; model-based analysis and, 141–143, 151–153, 156, 177, 567, 570; notation and, 32–34, 39; observation and, 31–32, 41–43; observed outcomes and, 33, 36, 41; overlap and, 314–316; pairwise randomized experiments and, 41, 221, 223, 232; populations and, 13, 33–35, 39–41; potential outcomes and, 23–24, 27–40; pre-treatment variables and, 32–33, 42; propensity score and, 35–40, 377, 380; randomized experiments and, 31–32, 35–36, 40–43; regression analysis and, 43; regular, 20, 32, 41 (*see also* regular assignment mechanisms); restrictions on, 37–39; samples and, 31–32, 39–40; sampling variances and, 437; sensitivity analysis and, 496, 499, 507; stratified randomized experiments and, 41–42, 191–192, 201–202; strongly ignorable treatment assignment and, 39, 43, 280; subpopulations and, 20, 35; super-populations and, 39–40; treatments and, 31–43; unbalanced, 32; unconfoundedness and, 31–32, 32, 38–43
- assignment probabilities, 20; classical randomized experiments and, 52–53; classification and, 31–32, 34–37, 39, 41, 43; matching and, 402; propensity score and, 282; sensitivity analysis and, 506–507, 509; unconfoundedness and, 257–259, 273
- assumptions, 6–8, 589–590; *a priori* approach and, 20 (*see also* *a priori* approach); assignment mechanisms and, 16, 32–34, 36, 39, 42–43; classical randomized experiments and, 53, 55; Fisher exact p-values and, 58, 62, 67–68, 74; general causal estimands and, 468–469; instrumental variables analysis and, 513–517, 520, 523–539, 542–584; labor market and, 240, 249t, 250; Lord’s paradox and, 16–18, 22, 28; matching and, 337, 345–347, 401–402, 404, 405, 418, 425n6, 426; model-based analysis and, 142, 144, 148–151, 153, 155–157, 160, 163, 165–172, 175–176, 181, 560–584; Neyman’s repeated sampling approach and, 84, 92, 94, 96, 98, 100–101, 104 overlap and, 309, 314, 332; pairwise randomized experiments and, 226 path diagrams and, 22; potential outcomes and, 25–26; propensity score and, 282, 284, 377–378, 383, 397–398; regression analysis and, 113, 115–116, 118–122, 126, 128, 130, 133–134; sampling variances and, 437, 452; sensitivity analysis and, 496–500, 503–506, 509; stratified

- assumptions (*cont.*)
- randomized experiments and, 189, 194, 199–202, 204, 206, 209; SUTVA (*see also* stable unit treatments value assumption (SUTVA)), 3; trimming and, 359, 361, 363, 367–368; unconfoundedness and, 257–265, 272, 278–280, 479–492, 495
- as-treated analysis, 515, 535–539
- asymptotic distribution: Fisher's exact p-values and, 81; instrumental variables analysis and, 581; matching and, 432; model-based analysis and, 174, 581; regression analysis and, 114, 135; sampling variances and, 447; stratified randomized experiments and, 216; trimming and, 360, 363–367; unconfoundedness and, 269
- asymptotic efficiency bounds, 365
- attributes: assignment mechanisms and, 33; instrumental variables analysis and, 516, 549–550, 553; potential outcomes and, 29; pre-treatment variables and, 15–16; propensity score and, 385
- average treatment effect, 19; classical randomized experiments and, 56; common estimator structure for, 441–445; conditional, 269; Fisher's exact p-values and, 57, 63, 81; frequentist perspective and, 172–174; general causal estimands and, 461, 465, 472, 474–475; instrumental variables analysis and, 515, 521, 529–531, 534–540, 547, 553–556, 558, 560, 565, 577–578, 581–583; labor market and, 240, 245–250, 253t; local (LATE), 515, 529–531, 534–535, 538, 540, 553–554, 565, 577, 582t, 583; matching and, 337–338, 341, 346, 401–402, 404, 407, 409, 414–420, 425–430; model-based analysis and, 141–142, 146–151, 156, 163–166, 168–173, 171–172, 175t, 181–183, 185, 560, 565, 577–578, 581, 583; Neyman's repeated sampling approach and, 83–109; pairwise randomized experiments and, 219, 222, 224–233; populations and, 98–101, 454–455; propensity score and, 283, 378, 382–383, 386–399; regression analysis and, 114–134; Rosenbaum approach and, 508; sampling variances and, 433–443, 450–460; sensitivity analysis and, 508; stratified randomized experiments and, 190, 194, 201–206, 210–211, 213; super-population and, 116–117, 171–172; trimming and, 359–366; unconfoundedness and, 268–269, 272, 274, 278, 489, 492t–493t, 494, 497–508; weighting and, 441–445
- balance: assignment mechanisms and, 32, 42; barbiturate data and, 319–322; classical randomized experiments and, 52, 55–56; conditional, 323f–325f, 331, 332, 337; direct assessment of, 313–314; equal percentage bias reducing (epbr) methods and, 347–348; labor market and, 246; Lalonde experimental data and, 326–327; Lalonde non-experimental data and, 328–333; lottery data and, 322–326; matching and, 337–358, 401, 404, 417, 428–431; model-based analysis and, 145; multivariate distributions and, 313–314; normalized difference and, 310–315, 318, 325, 327, 339, 350, 352, 354, 356f, 358, 361–362, 368, 370, 378–379, 386, 399, 404, 428, 435, 462; overlap and, 309–333, 336; propensity score and, 282–284, 286, 294–307, 314–317, 377–382, 385, 387, 396, 399; regression analysis and, 134; stratified randomized experiments and, 191–193; subsample controls and, 339–344; trimming and, 359–374; unconfoundedness and, 258, 266–269, 273, 276–278
- balancing scores, 266; coarseness of, 268; propensity score and, 265–266, 377–378, 381; unconfoundedness and, 265–266
- Bayesian approach: absence of covariates and, 150–163; analytic example and, 156–163; Fisher exact p-values and, 82, 144n1; four steps of, 153–156; frequentist perspective and, 172–174; general causal estimands and, 475; imputation and, 150–163; instrumental variables analysis and, 536, 573, 576; likelihood functions and, 178; model-based analysis and, 150–163; model-based inference and, 141, 143–163, 172–174, 178, 573, 576; pairwise randomized experiments and, 232–233; propensity score and, 306; sampling variances and, 434; stratified randomized experiments and, 213; unconfoundedness and, 271
- Bernoulli trials, 47–50, 53–55, 191, 507; assignment mechanism for, 49
- bias: equal percentage bias reducing (epbr) methods and, 347–348; Fisher's exact p-values and, 65; instrumental variables analysis and, 513, 520–521, 530, 533–538, 543; matching and, 337, 342, 345–349, 358, 402–404, 407, 409–410, 415–432; model-based analysis and, 142, 172; Neyman's repeated sampling approach and, 83–90, 92–94, 96, 98, 101–102, 104, 108, 110, 112; overlap and, 309, 311, 318, 325, 331; pairwise randomized experiments and, 225–227, 229, 234; potential outcomes and, 25–26; propensity score and, 281, 283, 285, 306, 377–378, 380–389, 392, 395, 397t, 398–399; reduction of, 346–347, 349, 358, 378, 383–388, 431, 450; regression analysis and, 113–114, 118–119, 122, 124–125, 128, 134; sampling variances and, 434, 436, 438–439, 445–448, 450–451, 457–459; sensitivity analysis and, 497–504; stratified randomized experiments and, 187, 201–204, 206, 211–212, 217; trimming and, 360, 374; unconfoundedness and, 257, 259–260, 266–268, 270, 275, 277, 279, 479–481, 487–488, 492
- blocking: classical randomized experiments and, 52; general causal estimands and, 463, 468–469, 472; matching and, 343, 401; propensity score and, 377–378, 382–383, 387, 394–396, 400; sampling variances and, 434–435, 444t, 453t; unconfoundedness and, 270, 274–275, 484, 490–491
- bootstrap, 434, 453t, 456, 459–460
- bounds: binary outcomes and, 500–508; efficiency, 268–270, 365; estimable parameters and, 501–502; Manski, 503; Neyman's repeated sampling approach and, 95, 101; partial identification approach and, 496; sensitivity analysis and, 496–509, 513; trimming and, 365; unconfoundedness and, 268–270

- cancer, 24, 370
- case-control designs, 43–44, 590
- catheterization, 360–362, 368–373
- causal effects, 589; assignment mechanisms and, 31, 36, 42; basics of, 3–9; Bayesian approach and, 141, 143–163, 172–174, 178, 573, 576; classical randomized experiments and, 47; in common usage, 7–8; definition of, 5–7, 21; dispersion and, 466–467; Fisher exact p-values and, 57, 62, 65, 78–79, 82; general causal estimands and, 462, 466–467, 473–474; instrumental variables analysis and, 513–517, 520, 522, 525–527, 529, 532, 535–536, 539–540, 542–544, 547–550, 554, 556–557, 559–560, 565, 577–578, 584; matching and, 337–338, 341, 358, 404, 407, 415, 421, 423, 428, 430; model-based analysis and, 141–142, 151, 153, 177–178, 560, 565, 577–578, 584; multiple units and, 3, 7–10, 21, 560–568, 578; Neyman's repeated sampling approach and, 102; overlap and, 309, 317–318, 320, 327–333, 336; post-treatment variables and, 6 (*see also* post-treatment variables); potential outcomes and, 14, 23–30; propensity score and, 281, 284–285, 297–298, 302, 306–307, 377–378, 382, 387, 392; pseudo, 298, 302, 479–482, 495; regression analysis and, 113, 115, 118, 126–127, 133–134; sampling variances and, 433–440; sensitivity analysis and, 496; stratified randomized experiments and, 195, 206; SUTVA and, 11 (*see also* stable unit treatments value assumption (SUTVA)); treatments and, 16 (*see also* treatments); trimming and, 359–360, 373–374; unconfoundedness and, 260–264, 268, 271, 276, 278, 479–495; unit-level, 7, 14–15, 18, 78, 126–127
- causal estimands: assignment mechanism and, 34; basics of, 17–19, 21; conditional potential outcome distributions and, 468–472; covariates and, 18–19; defined, 17; dispersion and, 466–467; drug treatment and, 18; general mechanisms for, 461–475; implementation and, 472–473; inequality and, 466–467; instrumental variables analysis and, 515, 535, 561, 569–570, 574; Lord's paradox and, 16–18, 22, 28; matching and, 401; model-based analysis and, 141–142, 147–148, 152, 155, 163, 170–171, 561, 569–570, 574; Neyman's repeated sampling approach and, 84; other estimands and, 467; overlap and, 336; populations and, 18–19; potential outcomes and, 25; pre-treatment variables and, 21; quantile treatment effects and, 465–466; sensitivity analysis and, 496; stratified randomized experiments and, 208; trimming and, 370; unconfoundedness and, 262–263, 276–277, 479–480, 489
- causal inference: assignment mechanism and, 13–15 (*see also* assignment mechanisms); attributes and, 15–16; causal effects in common usage and, 7–8; covariates and, 15–16; definition of causal effects and, 5–7; design stage and, 32; multiple units and, 3, 7–10, 21; populations and, 20–21; potential outcomes and, 3–5 (*see also* potential outcomes); pre-treatment variables and, 15–16; samples and, 20–21; stable unit treatments value assumption (SUTVA) and, 9–15, 21–22, 25, 33, 84, 188–189, 199, 498, 514, 516–517, 550, 589–590
- causality, 589; action and, 4; assignment mechanism and, xviii; association and, xvii; basics of, 1–22; description and, xvii; inference and, xviii, 3 (*see also* causal inference); matching and, 401; potential outcomes and, 24; treatments and, 4 (*see also* treatments); unit and, 4
- causal language, 3–4
- Children's Television Workshop, 220–228, 231, 233t, 234
- classical randomized experiments, 40: *a priori* approach and, 47, 51, 55; assignment mechanisms and, 40–41, 47–54; assignment probabilities and, 52–53; assumptions and, 53, 55; balance and, 52, 55–56; Bernoulli trials and, 47–50, 53–55; blocking and, 52; causal effects and, 47; classification and, 31; completely randomized experiments and, 50–56; control units and, 48–50, 55; covariates and, 47–49, 51–52, 55–56; drug treatment and, 49; estimators and, 55–56; multivariate distributions and, 313–314; notation and, 48, 50, 54; pairwise randomized experiments and, 47–48, 52–55; populations and, 47, 49, 51, 56; potential outcomes and, 47, 50–52, 55–56; pre-treatment variables and, 51–53, 55; probabilistic assignment and, 48, 53; propensity score and, 48–53; samples and, 50, 52–54, 56; stratified randomized experiments and, 47–48, 51–55; taxonomy of, 45–56; treatments and, 47–56; unconfoundedness and, 47–48, 53
- completely randomized experiments: assignment mechanisms and, 41; Bernoulli trials and, 191, 507; classical randomized experiments and, 47–56; completely randomized experiments and, 21, 25; Fisher exact p-values and, 57–82; instrumental variables analysis and, 514–516, 560, 568; matching and, 337, 352; model-based analysis and, 141–186, 560, 568; Neyman's repeated sampling approach and, 21, 25–26, 83–112; overlap and, 318; pairwise randomized experiments and, 219, 223, 225–226, 228, 232, 234; potential outcomes and, 25–26; propensity score and, 282, 378, 387–388, 390; regression analysis and, 113–140; sensitivity analysis and, 498, 503, 507; stratified randomized experiments and, 187–195, 197, 201, 204, 207, 211–212; unconfoundedness and, 257, 259, 267, 270, 273–274
- complier average causal effect (CACE), 515, 529, 540
- compliers: instrumental variables analysis and, 515–516, 523–546, 549–559, 562t, 563–565, 569–572, 575–584; latent strata and, 515; model-based analysis and, 562t, 563–565, 569–572, 575–584
- conditional average treatment effect, 269
- conditional distribution: general causal estimands and, 465, 468; instrumental variables analysis and, 572–574, 578; model-based analysis and, 143, 144n1, 151–155, 157–158, 160, 163, 167–173, 176, 178, 182, 185; overlap and, 314, 316; unconfoundedness and, 261, 271, 479, 489
- conditional independence assumption: assignment mechanisms and, 43; Dawid, 520; instrumental variables analysis and, 520, 568, 574;

- conditional independence assumption (*cont.*)  
 model-based analysis and, 568, 574;  
 unconfoundedness and, 260, 280, 483–487
- conditional mean: instrumental variables analysis and, 532; matching and, 346, 417; model-based analysis and, 162, 176; propensity score and, 302, 316; regression analysis and, 114, 117, 119, 133, 162, 176, 272, 302, 316, 346, 417, 450, 532; sampling variances and, 450; unconfoundedness and, 272
- confidence intervals: instrumental variables analysis and, 521–522, 531, 547–548; labor market and, 240, 242, 245–247, 253; model-based analysis and, 142, 174; Neyman's repeated sampling approach and, 84, 87, 92–96, 102–103; overlap and, 335–336; regression analysis and, 120, 134; sampling variances and, 433, 460; stratified randomized experiments and, 187, 203–204, 227–228
- control distribution, 312–313, 349
- control pairs, 11
- control treatments: assignment mechanisms and, 32–34, 36, 38; basics of, 4, 8, 13, 16–17; classical randomized experiments and, 47–48, 50–52; Fisher exact p-values and, 57; instrumental variables analysis and, 514, 525, 527, 530, 532, 536–537, 539, 554, 565, 569, 575; labor market and, 246; matching and, 412, 417; model-based analysis and, 147, 169–170, 565, 569, 575; Neyman's repeated sampling approach and, 83, pairwise randomized experiments and, 222, 227; potential outcomes and, 29; propensity score and, 282; sensitivity analysis and, 500; stratified randomized experiments and, 187, 192, 210–211; unconfoundedness and, 479, 485
- control units: assignment mechanisms and, 35, 41–42; classical randomized experiments and, 48–50, 55; Fisher's exact p-values and, 67–69, 75–78; general causal estimands and, 469, 472; instrumental variables analysis and, 515, 583; labor market and, 246; matching and, 338, 341, 344–345, 349–350, 357, 401–411, 416, 419–421, 424–427, 431; model-based analysis and, 181, 193–198, 583; Neyman's repeated sampling approach and, 87, 90, 94, overlap and, 309, 311–313, 319, 320; pairwise randomized experiments and, 220–221, 223–224, 225t, 229, 233; potential outcomes and, 29–30; propensity score and, 282, 292–293, 302, 377, 380–385, 399; regression analysis and, 127; sampling variances and, 433–434, 441–443, 447–448, 451, 453, 459–460; sensitivity analysis and, 498; trimming and, 360–361, 368, 371t–372t, 374; unconfoundedness and, 257, 259–260, 263, 266–267, 269, 274–279, 479–481, 488, 494
- counterfactuals, 5, 8, 517–518, 571
- covariance matrices: Fisher's exact p-values and, 71; matching and, 342, 345, 347–348, 410, 428; model-based analysis and, 156, 165, 174, 180–186; overlap and, 314; pairwise randomized experiments and, 239; regression analysis and, 117, 122, 130, 135–136, 138–140; stratified randomized experiments and, 216–217
- covariates, 590; ability to adjust for differences and, 317–318; additional linear terms and, 287; assignment mechanisms and, 20, 31–39, 42; attributes and, 15–16; balance and, 277, 282, 296–306, 309, 316–318, 329, 336–337, 359, 380, 428–429; basic, 386–387; causal estimands and, 18–19; classical randomized experiments and, 47–49, 51–52, 55–56; distance measures and, 410–412; Fisher exact p-values and, 59, 78–80; general causal estimands and, 462–469, 472–474; imputation and, 150–163, 169–171; instrumental variables analysis and, 514–515, 526, 538, 543, 551, 556, 558, 560–583; interactions and, 125–127, 285–288; labor market and, 240, 242–243, 246–248, 250–253; limits on increases in precision and, 128–129; Lord's paradox and, 17–18; matching and, 337–358, 401–404, 407–432; model-based analysis and, 142–144, 150–151, 153–161, 169–171, 173–176, 177t, 560–583; Neyman's repeated sampling approach and, 84–85, 101–102, 104; normalized difference and, 310–315, 318, 325, 327, 339, 350, 352, 354, 356f, 358, 361–362, 368, 370, 378–379, 386, 399, 404, 428, 435, 462; overlap and, 309–336; pairwise randomized experiments and, 219–222, 229–233; populations and, 20–21; propensity score and, 282–308, 377–387, 390–399; quadratic terms and, 287–288; regression analysis and, 114–134; sampling variances and, 434–437, 440–452, 456, 460; sensitivity analysis and, 496–509; single binary, 259, 269–270, 282, 360, 362–365, 437; stratified randomized experiments and, 187, 190–191, 195; trimming and, 359–374; unconfoundedness and, 257–260, 262, 265–280, 479–494
- Cowles Commission, 29
- Current Population Survey (CPS), 325t, 329–335, 464t, 495
- Data Augmentation (DA) methods, 574, 577, 585
- Dawid conditional independence assumption, 520
- defiers: instrumental variables analysis and, 542, 545–546, 549–557, 559, 563–565, 574; model-based analysis and, 563–565, 574
- de Finetti's theorem, 152, 169, 178, 232, 271, 570
- design phase: matching and, 337, 358; trimming and, 373; unconfoundedness and, 276–278
- difference in difference (DID) methods, 43–44, 432, 590
- dispersion: causal effects and, 466–467; Fisher's exact p-values and, 70–72; model-based analysis and, 141, 150, 170; overlap and, 310, 312, 314, 321; propensity score and, 394; sampling variances and, 466–467; stratified randomized experiments and, 189, 198
- double-blind experiments, 515–516, 526–528, 539, 550
- drug treatments: assignment mechanisms and, 34, 40; causal estimands and, 18; classical randomized experiments and, 49; drug trials, 12–13, 191, 527, 552; Fisher's exact p-values and, 59; instrumental variables analysis and, 515, 527–528, 552; Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) and, 115–116, 131–133; matching and, 340t, 351t, 353t, 357t; overlap and, 319, 320t; placebos and, 11–12, 49, 115–116, 131, 528; potential

- outcomes and, 12–16; propensity score and, 285t, 289t, 290, 291t, 301t, 304t–305t; regression analysis and, 115–116, 131–132, 134; Reinisch barbiturate exposure data and, 284–290, 294–296, 300–306, 319–322, 325t, 338–339, 340t, 344, 345t, 349–358; stratified randomized experiments and, 191; SUTVA and, 12–15; unconfoundedness and, 262, 265
- Dufo–Hanna–Ryan teacher-incentive experiment, 84–85, 87, 94–97, 102–103
- empirical distribution: Fisher’s exact p-values and, 66, 69, 72; general causal estimands and, 465; matching and, 339; model-based analysis and, 149t; overlap and, 312–313
- equal percentage bias reducing (epbr) methods, 347–348
- estimators: average treatment effect and, 441–445, 452–455; bias and, 65 (*see also* bias); blocking, 274–275, 382–383, 394–396, 435, 463; bootstrap, 434, 453t, 456, 459–460; classical randomized experiments and, 55–56; difference, 346, 442; efficiency bounds and, 268–270; Fisher’s exact p-values and, 65, 68, 71; general causal estimands and, 463; heteroskedasticity and, 121, 125, 389, 450, 453t; homoskedasticity and, 120–121, 125, 196, 234, 341, 366–367, 398, 426, 452, 453t; instrumental variables analysis and, 515–516, 520–521, 530–531, 534–538, 541, 548, 554–556, 558, 563; internal validity and, 359, 365; least squares, 114, 118–128, 130 (*see also* least squares estimators); matching and, 275–276, 337, 341, 345–346, 358, 401–432, 443; mixed, 276; model-based analysis and, 147, 165, 174, 270–271, 563; moment-based, 530–531; natural, 86, 212, 219, 226, 233, 363, 402, 437–440, 458; Neyman’s repeated sampling approach and, 83–84, 86–102, 104, 106–109; overlap and, 314, 336; pairwise randomized experiments and, 219, 224–227, 229–231, 233–234, 236, 239, 457–459; precision of, 55; propensity score and, 273–275, 281–282, 297, 307, 378–384, 386–400; regression, 113–114, 118–122, 124–128, 130, 132, 134–135, 137, 229, 272–274, 393, 399, 432, 442; regular, 259; sampling variances and, 121, 433–460; sensitivity analysis and, 497; simple, 56, 378, 386–387, 446–451, 530–531; strategies for, 270–276; stratified randomized experiments and, 201–207, 211–212, 216; subclassification, 382–384, 388, 394–399, 443–444, 452, 456–457, 460, 497; super-population limits and, 120; trimming and, 359–360, 363–366; unconfoundedness and, 257, 260, 268–277; weighting, 273–275, 378, 392–399, 432, 441–445
- exclusion restrictions: alwaystakers and, 549; compliers and, 527–528 (*see also* compliers); defiers and, 542, 545–546, 549–553, 555–557, 559, 563–565, 574; discussion of, 528–529; instrumental variables analysis and, 515–516, 525–532, 536–540, 542, 545–546, 549–555, 558–565, 568–579, 581, 584; irregular assignment mechanisms and, 20, 42; model-based analysis and, 560–565, 568–579, 581, 584; nevertakers and, 545–546, 549–555, 562t, 563–565, 568–572, 574–575, 577–579, 581, 584; noncompliers and, 526–527; SUTVA and, 10–13
- exogeneity, 43, 263, 280
- Expectation Maximization (EM) algorithm, 577
- finite samples, 18; assignment mechanisms and, 31; Fisher exact p-values and, 70; general causal estimands and, 465, 474; instrumental variables analysis and, 520; labor market and, 253t; matching and, 403; model-based analysis and, 141, 172, 181, 185; Neyman’s repeated sampling approach and, 83, 89, 96, 98–99, 104–106; overlap and, 309; pairwise randomized experiments and, 222, 226, 232; propensity score and, 35, 297, 393; regression analysis and, 113–114, 117–118, 122, 124–125, 128; sensitivity analysis and, 498, 501; stratified randomized experiments and, 190, 201; super-populations and, 21; trimming and, 366; unconfoundedness and, 259, 269, 275; variances and, 436–437, 454–455
- Fisher information matrix, 174, 180
- Fisher’s exact p-values: *a priori* approach and, 58, 70, 80; assignment mechanisms and, 58; assumptions and, 58, 62, 67–68, 74; asymptotic distribution and, 81; Bayesian approach and, 82, 144n1; bias and, 65; causal effects and, 57, 62, 65, 78–79, 82; Children’s Television Workshop and, 222–224; choice of null hypothesis and, 63–64; computation of, 75–78; control units and, 67–69, 75–78; covariance matrices and, 71; covariates and, 59, 78–80; development of, 57–58; dispersion and, 70–72; drug treatment and, 59; empirical distribution and, 66, 69, 72; honey study and, 59–63, 67, 70, 74–77, 80–81; instrumental variables analysis and, 540; interval estimation and, 58, 74–75, 82; *J* strata case and, 196–197; Kolmogorov-Smirnov statistic and, 69–70, 81; labor market and, 240, 242–244, 243t, 249, 253; least squares estimators and, 68, 79; maximum likelihood and, 68–69, 72; Mahalanobis metric and, 71; model-based analysis and, 68–69, 82, 142; multiple components and, 70–71; Neyman’s repeated sampling approach and, 83, 85, 102, 104; normal distribution and, 66, 69, 73; notation and, 57; observation and, 67, 74, 75t, 80; observed outcomes and, 57–58, 60–61, 64, 67–68, 70, 75t, 78, 80; observed value and, 58, 62t, 68, 75–78, 80; outliers and, 65–67, 72–73; pairwise randomized experiments and, 220, 222–224, 233; populations and, 61, 72; post-treatment variables and, 80; potential outcomes and, 17, 57–80, 83; pre-treatment variables and, 57, 64, 78–79, 81; Project Star and, 197–201; propensity score and, 297; quantiles and, 66; randomization distribution and, 57–58, 62t, 63, 66, 70, 74–75, 80–81, 83; random variables and, 72; rank statistics and, 66–68; regression analysis and, 79–82, 129–130, 133t; residuals and, 82; robustness and, 66; samples and, 57, 59, 62–63, 66–72, 76–77, 81; sensitivity analysis and, 506; sharp null hypothesis and, 57–83, 93, 189, 192,



- Fisher's exact p-values: *a priori* approach and (*cont.*) 195, 240, 337; simulation and, 58, 72–74, 77t; small simulation study and, 72–74; statistical power and, 58, 64, 80; stochastic assignment vector and, 57–58; stratified randomized experiments and, 188–201; subsamples and, 66; test statistic and, 57–81; transformations and, 65; treatments and, 57–82; two strata case and, 192–196; typical effect and, 57; Wilcoxon rank sum test and, 67, 82
- frequentist perspective, 172–174
- F-statistic, 249, 298–300
- general causal estimands: assumptions and, 468–469; Bayesian approach and, 475; blocking and, 463, 468–469, 472; causal effects and, 462, 466–467, 473–474; conditional distribution and, 465, 468; control units and, 469, 472; covariates and, 462–469, 472–474; empirical distribution and, 465; estimators and, 463; Gini coefficient and, 466–467, 474; implementation and, 472–473; imputation and, 461–462, 475; inequality and, 461, 466–467, 474; marginal distribution and, 464, 467; model-based analysis and, 461, 467–468, 474; multiple block, 469, 472; National Supported Work (NSW) job-training data and, 462–465, 470t–471t, 473–474; normal distribution and, 468; normalized difference and, 462; observed outcomes and, 464; other estimands and, 467; outliers and, 466; populations and, 465–467, 473–474; posterior distribution and, 467, 469, 472–473; potential outcomes and, 461–474; pre-treatment variables and, 461, 468; prior distribution and, 468, 472; propensity score and, 462–463, 469; quantile treatment effects and, 465–466; randomized experiments and, 467; regression analysis and, 461–463, 468; robustness and, 466; samples and, 462, 464–474; single block, 468–469; standard deviation and, 466, 472; statistical model and, 472; subclassification and, 464t; subsamples and, 462, 472–473; super-populations and, 465, 473–474; treatments and, 461–469, 472–475; unconfoundedness and, 468; weighting and, 462
- general equilibrium, 11
- Gini coefficient, 466–467, 474
- gross domestic product (GDP), 22
- heteroskedasticity, 121, 125, 389, 450, 453t
- homoskedasticity, 120–121, 125, 196, 234, 341, 366–367, 398, 426, 452, 453t
- honey study, 59–63, 67, 70, 74–77, 80–81
- Horvitz-Thompson estimators, 282, 378, 379t, 392–400, 443
- ignorable treatment assignment, 39
- imputation: analytic example and, 156–163; Bayesian approach and, 150–163; covariates and, 150–163, 169–171; de Finetti's theorem and, 152, 169, 178; estimators and, 270–271; general causal estimands and, 461–462, 475; instrumental variables analysis and, 530, 560, 577, 581; labor market and, 251t, 252–253; matching and, 338; missing outcomes and, 160–161; model-based analysis and, 141, 146–163, 164t, 169–171, 177, 187–188, 209, 220, 231, 251t, 252, 270–271, 275–276, 309, 338, 387, 461, 560, 577, 581; naive approaches to, 146–150; overlap and, 309; pairwise randomized experiments and, 220, 231; propensity score and, 378, 387; regression analysis and, 113, 126–127; sampling variances and, 434, 451; sophisticated approaches to, 146–150; stratified randomized experiments and, 187–189, 209; SUTVA violations and, 188; unconfoundedness and, 270–271, 273, 275–276
- incentives: Duflo–Hanna–Ryan teacher-incentive experiment and, 84–85, 87, 94–97, 102–103; instrumental variables analysis and, 540, 550, 552
- individualistic assignment: definition of, 38; overlap and, 316; as restriction, 37–39, 43; unconfoundedness and, 259, 261–262
- inequality: general causal estimands and, 461, 466–467, 474; trimming and, 367–368
- influenza vaccination data, 560–567, 578–583
- instrumental variables analysis: always-takers and, 545–546, 549–555, 562t, 563–565, 568–572, 574–579, 581, 583; Angrist study and, 543–544, 547; assignment mechanisms and, 43, 527, 567, 570; assignment vs. receipt effects and, 513, 516, 527, 538; assumptions and, 513–517, 520, 523–539, 542–584; as-treated analysis and, 515, 535–539; asymptotic distribution and, 581; average treatment effect and, 515, 521, 529–531, 534–540, 547, 553–556, 558, 560, 565, 577–578, 581–583; Bayesian approach and, 536, 573, 576; behavioral equation and, 532; bias and, 513, 520–521, 530, 533–538, 543; causal effects and, 513–517, 520, 522, 525–527, 529, 532, 535–536, 539–540, 542–544, 547–550, 554, 556–557, 559–560, 565, 577–578, 584; causal estimands and, 515, 535, 561, 569–570, 574; completely randomized experiments and, 514–516, 560, 568; compliance status and, 522–526, 544–546; compliers and, 515–516, 523–546, 549–559, 562t, 563–565, 569–572, 575–584; conditional distribution and, 572–574, 578; conditional independence assumption and, 520, 568, 574; conditional mean and, 532; conditioning and, 265–266; confidence intervals and, 521–522, 531, 547–548; control units and, 515, 583; covariates and, 514–515, 526, 538, 543, 551, 556, 558, 560–583; data augmentation (DA) methods and, 574, 577, 585; defiers and, 542, 545–546, 549–557, 559, 563–565, 574; double-blind experiments and, 515–516, 526–528, 539, 550; estimators and, 515–516, 520–521, 530–531, 534–538, 541, 548, 554–556, 558, 563; exclusion restrictions and, 515–516, 525–532, 536–540, 542, 549–553, 558–560, 562t, 563, 568–569, 572, 574–575, 579, 584; Expectation Maximization (EM) algorithm and, 577; Fisher's exact p-values and, 540; imputation and, 530, 560, 577, 581; incentives and, 540, 550, 552; influenza vaccination data and, 560–567, 577–583; intention-to-treat (ITT) effects and, 514–516, 519–531, 534–541, 546–558, 562–567, 582t; latent strata and, 515; least squares estimators and, 533–534, 557–558; linear models and, 531–535; marginal

- distribution and, 573; model-based analysis and, 515–516, 530, 559–584; moment-based, 530–531; monotonicity and, 542, 551–556, 559–565, 575, 579; nevertakers and, 545–546, 549–555, 562t, 563–565, 568–572, 574–575, 577–579, 581, 583–584; noncompliers and, 515, 532–533, 536–539, 544–545, 553–555, 559, 569, 572, 579; OLS estimators and, 534, 558; one-sided noncompliance and, 513–541; per protocol, 514, 535–540; potential outcomes and, 513, 516–517, 520, 522–525, 528, 530, 532–534, 539–540, 545–546, 549, 553–554, 557, 559–560, 563–583; pre-treatment variables and, 527, 538, 546–547, 561, 567; principal stratification and, 514; randomization distribution and, 520–521; regression analysis and, 532–534, 557–558, 565–566, 578; robustness and, 578; sampling variances and, 520–521, 530–531, 541, 547–548; simulation and, 561, 566, 572, 574–577; Sommer–Zeger dataset and, 516–517, 520–521, 528, 538–541; stable unit treatment value assumption (SUTVA) and, 514, 516–517, 550, 589–590; statistical model and, 560, 581; stochastic treatments and, 526–527, 551, 553, 568, 577; subsamples and, 518, 527, 541, 561; traditional economic methods and, 556–558; two-sided noncompliance and, 542–559; unconfoundedness and, 513–516, 520–521, 525–526, 530, 534–539, 543, 547, 567, 572, 584; vitamin supplements and, 516–517, 520–521, 528, 538–541
- intention-to-treat (ITT) effects: cholesterol data and, 131; compliance status and, 522–526; estimands for, 519–520; instrumental variables analysis and, 514–516, 519–531, 534–541, 546–558, 561–567, 582t; model-based analysis and, 561–567, 582t; outcome of interest and, 521–522; random assignment and, 520; receipt of treatment and, 520–521, 524; regression analysis and, 131
- internal validity, 359, 365
- interval estimators: Fisher's exact p-values and, 58, 74–75, 82; model-based analysis and, 142; Neyman's repeated sampling approach and, 83–84, 87, 102–103; sampling variances and, 436; stratified randomized experiments and, 213
- irregular assignment mechanisms, 20, 42–43
- It's a Wonderful Life* (film), 7–8
- Journal of the Royal Statistical Society, 104
- kernel smoothing, 306, 432
- Kolmogorov–Smirnov statistic, 69–70, 81
- lasso method, 303–306
- latent strata, 515, 590
- least squares estimators: Fisher's exact p-values and, 68, 79; instrumental variables analysis and, 533–534, 557–558; labor market and, 247–249; matching and, 404, 418, 420, 428–430; model-based analysis and, 173, 179; ordinary (OLS), 28, 113, 118, 127, 135, 173, 205, 389, 404, 418, 428, 534, 558; pairwise randomized experiments and, 230–231; potential outcomes and, 28; propensity score and, 387–393, 397–398; regression analysis and, 113–114, 118–130, 134–135; sampling variances and, 435–436, 442, 444, 456–459; stratified randomized experiments and, 205–207, 214; unconfoundedness and, 272
- likelihood: classical randomized experiments and, 56; Fisher's exact p-values and, 68–69, 72; instrumental variables analysis and, 568, 573–577, 580–583; maximum likelihood estimation and, 68–69, 72, 173–174, 180, 286, 307–308, 576–577, 581–583; model-based analysis and, 154, 158–159, 166–167, 172–174, 178, 180–183, 568, 573–577, 580–583; propensity score and, 284–290, 307–308; trimming and, 368
- Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), 115–116, 131–133
- local average treatment effect (LATE), 515, 529–531, 534–535, 538
- Lord's paradox, 16–18, 22, 28
- lung cancer, 24, 370
- Mahalanobis metric: Fisher's exact p-values and, 71; matching and, 338–339, 342, 344–358, 410–412, 427–430; overlap and, 314; sampling variances and, 448
- manipulation, 3–5, 7, 21, 263, 524. *See also* treatments
- marginal distribution: general causal estimands and, 464, 467; instrumental variables analysis and, 573; model-based analysis and, 153–154, 157–158, 160, 169–170, 573; overlap and, 314, 316; trimming and, 367; unconfoundedness and, 269–270
- Markov–Chain–Monte Carlo (MCMC) methods, 142–143, 178–179, 213, 469, 472
- matching: approximate, 447–449; *a priori* approach and, 338, 341, 343, 409, 412; assignment probabilities and, 402; assumptions and, 337, 345–347, 401–402, 404, 405–409, 418, 425n6, 426; asymptotic distribution and, 432; balance and, 337–358, 401, 404, 417, 428–431; bias and, 337, 342, 345–349, 358, 402–404, 407, 409–410, 415–432; blocking and, 343, 401; caliper methods and, 344; causal effects and, 337–338, 341, 358, 404, 407, 415, 421, 423, 428, 430; causal estimands and, 401; causality and, 401; completely randomized experiments and, 337, 352; conditional mean and, 346, 417; control distribution and, 349; covariance matrices and, 342, 345, 347–348, 410, 428; covariates and, 337–358, 401–404, 407–432; design phase and, 337, 358; distance measures and, 410–412; drug treatment and, 340t, 351t, 353t, 357t; equal percentage bias reducing (epbr) methods and, 347–348; estimators and, 275–276, 337, 341, 345–346, 358, 401–432, 443; exact, 275, 405–408, 410, 415; full sample and, 427–428; hybrid methods for, 343; imputation and, 338; inexact, 403, 407–410, 412, 415, 434; kernel, 432; least squares estimators and, 404, 418, 420, 428–430; Mahalanobis metric and, 338–339, 342, 344–358, 410–412, 427–430; model-based analysis and, 337–338; multiple, 403, 425, 432, 450–451; normalized difference and, 339, 350,

matching: approximate (*cont.*)

352, 354, 356f, 358, 404, 428; number of matches and, 425–427; overlap and, 309, 321, 336; pairwise randomized experiments and, 219, 234, 402, 406–407, 409–410, 425; populations and, 338, 346, 407–408, 415–416, 426–427, 431; post-treatment variables and, 415; potential outcomes and, 338, 343, 401–402, 404, 407, 409, 412, 415–417, 419, 421; pre-treatment variables and, 338, 401–402, 405, 411, 415–416, 418, 424; propensity score and, 337–359, 361, 374, 383, 404–405, 409–410, 416–417, 431–432; randomized experiments and, 337, 341, 343, 349, 352, 402–403, 407, 409; regression analysis and, 346, 404, 416–424, 427–428, 430–432; Reinisch barbiturate exposure data and, 338–339, 340t, 344, 345t, 349–358; rejecting poor quality matches, 343–354; replacement and, 277, 338–339, 344, 403, 405–410, 412–414, 420, 422t, 424–425, 427–431, 436, 457–458; residuals and, 418; robustness and, 337–338, 341, 349, 430–432; samples and, 337–358, 401–421, 424–431; sampling variances and, 341, 402–403, 407, 409, 424, 426, 428, 431, 434–436, 443–444, 446–447, 449–450, 452–460; sharp null hypothesis and, 337; simulation and, 432, 434, 460; standard deviation and, 339, 350, 356; super-populations and, 407, 415–416, 426; theoretical properties of, 345–349; treatments and, 343, 345–350, 352, 358, 401–432; unconfoundedness and, 270, 273, 275–277, 341, 346, 361, 401–402, 404, 407, 409, 484; weighting and, 343, 432

minimum wage, 402, 404–405, 412–415, 420, 428–432

missingness, 43

model-based analysis: alwaystakers and, 562t, 563–565, 568–572, 574–579, 581, 583; analytic example and, 156–163; a priori approach and, 144n1, 175, 571, 576; assignment mechanisms and, 141–143, 151–153, 156, 177, 567, 570; assumptions and, 142, 144, 148–151, 153, 155–157, 160, 163, 165–172, 175–176, 181, 560–584; asymptotic distribution and, 174, 581; average treatment effect and, 141–142, 146–151, 156, 163–166, 168–173, 175t, 181–183, 185, 560, 565, 577–578, 581, 583; balance and, 145; Bayesian approach and, 141, 143–163, 172–174, 178, 573, 576; bias and, 142, 172; causal effects and, 141–142, 151, 153, 177–178, 560, 565, 577–578, 584; causal estimands and, 141–142, 147–148, 152, 155, 163, 170–171, 561, 569–570, 574; completely randomized experiments and, 141–186, 560, 568; compliers and, 562t, 563–565, 569–572, 575–583; conditional distribution and, 143, 144n1, 151–155, 157–158, 160, 163, 167–173, 176, 178, 182, 185, 572–574, 578; conditional independence assumption and, 568, 574; conditional mean and, 162, 176; confidence intervals and, 142, 174; control units and, 181, 583; covariance matrices and, 156, 165, 174, 180–186; covariates and, 142–144, 150–151, 153–161, 169–171, 173–176, 177t, 560–583; data augmentation (DA) methods and, 574, 577, 585; defiers and, 563–565, 574; de Finetti's theorem and, 152, 169, 178; derivations

for, 572–574; dispersion and, 141, 150, 170; empirical distribution and, 149t; estimators and, 147, 165, 174, 270–271, 563; exclusion restrictions and, 560, 562t, 563, 568–569, 572, 574–575, 579, 584; Expectation Maximization (EM) algorithm and, 577; finite samples and, 141, 172, 181, 185; Fisher's exact p-values and, 68–69, 82, 142; frequentist perspective and, 172–174; Gaussian distributions and, 152, 156, 159–160; general causal estimands and, 461, 467–468, 474; imputation and, 141, 146–163, 164t, 169–171, 177, 187–188, 209, 220, 231, 251t, 252, 270–271, 275–276, 309, 338, 387, 461, 560; influenza vaccination data and, 560–567, 577–583; inputs into, 152–153, 570–574; instrumental variables analysis and, 515–516, 530, 559–584; intention-to-treat (ITT) effects and, 562–567, 582t; interval estimators and, 142; joint distribution and, 143, 151–158, 160, 163, 165–167, 169–177, 560, 570–574, 582; least squares estimators and, 173, 179; likelihood and, 154, 158–159, 166–167, 172–174, 178, 180–183, 568, 573–577, 580–583; marginal distribution and, 153–154, 157–158, 160, 169–170, 573; matching and, 337–338, 403, 416–417; monotonicity and, 560–565, 575, 579; nevertakers and, 562t, 563–565, 568–572, 574–575, 577–579, 581, 583–584; Neyman's repeated sampling approach and, 141–142, 144n1, 169, 171, 175, 560, 565–567; overlap and, 309, 336; pairwise randomized experiments and, 220, 231–234; posterior distribution and, 144, 151–155, 158–163, 166–167, 170–172, 176–180, 183, 185, 561, 566, 570, 572–583; potential outcomes and, 141–157, 160, 163–177, 181–182, 185, 560, 563–583; pre-treatment variables and, 142, 561, 567; prior distribution and, 143–144, 152, 154–156, 158–160, 163, 166–167, 170–172, 174–176, 178–183, 185, 565–567, 572–573, 576–577, 579–582; Project Star and, 209–211; random variables and, 141, 144, 151, 173, 179–180, 182; regression analysis and, 114, 134, 141–142, 173, 175, 179–180, 565–566, 578; regular assignment mechanisms and, 153, 567; robustness and, 142, 152, 156, 578; sampling variances and, 172, 450; simulation and, 142–144, 152, 163–165, 171, 176–180, 561, 566, 572, 574–577; stable unit treatment value assumption (SUTVA) and, 589–590; stochastic treatments and, 141–142, 162, 568, 577; stratified randomized experiments and, 187–188, 207–212; super-population and, 171–172; Taylor series and, 174; treatments and, 141–142, 145–151, 155–156, 162–166, 168–y178, 181–183, 185, 560–569, 575, 577–584; trimming and, 366–367, 378, 385, 387; two-sided noncompliance and, 560–584; unconfoundedness and, 270–271, 275–276, 484, 567, 572, 584

monotonicity: description of, 551–553; instrumental variables analysis and, 542, 551–556, 559–565, 575, 579; model-based analysis and, 560–565, 575, 579; as no-defier assumption, 542; relaxing condition of, 555–556; traditional economic methods and, 556–558



- multiple units: basics of, 3, 7–10, 21; causal effects and, 3, 7–10, 21, 560–568, 578; Neyman's repeated sampling approach and, 87–92; populations and, 560–568, 578; stable unit treatments value assumption (SUTVA) and, 9–15, 21–22, 25, 33, 84, 188–189, 199, 498, 514, 516–517, 550
- National Supported Work (NSW) job-training data: general causal estimands and, 462–465, 470t–471t, 473–474; model-based analysis and, 144–150, 156, 164t, 174–177, 324f, 328, 330–335, 463t–464t, 470t–471t; overlap and, 324f, 328, 330–335
- nevertakers: instrumental variables analysis and, 545–546, 549–555, 562t, 563–565, 568–572, 574–575, 577–579, 581, 583–584; model-based analysis and, 562t, 563–565, 568–572, 574–575, 577–579, 581, 583–584
- Neyman's repeated sampling approach: *a priori* approach and, 96, assumptions and, 84, 92, 94, 96, 98, 100–101, 104, 110; bias and, 83–90, 92–94, 96, 98, 101–102, 104, 108, 110, 112; bounds and, 95, 101; causal effects and, 102; causal estimands and, 84; Children's Television Workshop and, 224–228; completely randomized experiments and, 21, 25–26, 83–112; confidence intervals and, 84, 87, 92–96, 102–103; control units and, 87, 90, 94, covariates and, 84–85, 101–102, 104; development of, 83–84; Duflo-Hanna-Ryan teacher-incentive experiment and, 84–85, 87, 94–97, 102–103; estimators and, 83–84, 86–102, 104, 107–109; Fisher's exact p-values and, 63, 83, 85, 102; inference for average treatment effects and, 98–101; instrumental variables analysis and, 520, 530, 547–548, 551, 560, 565–567; interval estimators and, 83–84, 87, 102, 103; joint distribution and, 96; labor market and, 240, 245–247, 250, 253; model-based analysis and, 141–142, 144n1, 169, 171, 175, 560, 565–567; multiple-unit variance and, 89–92; normal distribution and, 93, 96; notation and, 83; null hypothesis and, 83, 93, 97–98, 102, 104, 551; observation and, 92; outliers and, 98; pairwise randomized experiments and, 219–220, 224–228, 233; populations and, 83–86, 89–90, 92–94, 110n2; post-treatment variables and, 85t, 103t; potential outcomes and, 85–96, 99–100, 106, 108; pre-treatment variables and, 85t, 102, 103t; Project Star and, 203–205; propensity score and, 297, 377, 388–390; pseudo-outcomes and, 102; randomization distribution and, 83–84, 86–88, 96, 99–100, 102, 106–107; random variables and, 88, 105; regression analysis and, 113–114, 121, 134; sampling variances and, 84, 87–104, 105–109, 438–439; sensitivity analysis and, 498; stable unit treatment value assumption (SUTVA) and, 84, 188; standard deviation and, 85; stochastic treatments and, 84, 99; stratified randomized experiments and, 187–189, 193, 201–205, 213; test statistics and, 97; treatments and, 83–112; trimming and, 363; two strata case and, 201–203; two-unit variance and, 87–89; unconfoundedness and, 259
- noncompliance. *See* instrumental variables analysis
- normalized difference: general causal estimands and, 462; matching and, 339, 350, 352, 354, 356f, 358, 404, 428; overlap and, 310–315, 318, 325, 327; propensity score and, 378–379, 386, 399; sampling variances and, 435; trimming and, 361–362, 368, 370
- normalized rank, 67, 195, 221t, 242
- notation: assignment mechanisms and, 32–34, 39; classical randomized experiments and, 48, 50, 54; Dawid and, 119, 260, 520; Fisher exact p-values and, 57; Holland and, 21; instrumental variables analysis and, 516–518, 520, 524, 542, 569, 571, 575; Lord's paradox and, 17; matching and, 344, 346, 406, 409, 418, 425; model-based analysis and, 151, 569, 571, 575; Neyman and, 21, 25–26, 27, 30, 57, 83; observed outcomes and, 27–28; observed value and, 13, 30; pairwise randomized experiments and, 220–221; potential outcomes and, 23–30; propensity score and, 282, 381; regression analysis and, 114, 117, 119, 122; sampling variances and, 445; sensitivity analysis and, 503; stratified randomized experiments and, 190, 192, 199, 205, 209; unconfoundedness and, 260, 268, 483, 485
- null hypothesis: Fisher's exact p-values and, 57–64, 66, 68–72, 74–81, 551; labor market and, 242–243, 249; Neyman's repeated sampling approach and, 83, 93, 97–98, 102, 104, 551; overlap and, 311; pairwise randomized experiments and, 223–224; propensity score and, 285, 287–288, 295, 298–302, 381–382, 385; regression analysis and, 130–133, 139; sensitivity analysis and, 500, 506–507; sharp, 57 (*see also* sharp null hypothesis); stratified randomized experiments and, 189, 195–201, 214; SUTVA and, 22; unconfoundedness and, 278, 480–481, 485–486, 495
- observational study, 41
- observed outcomes: assignment mechanisms and, 33, 36, 41; average, 15, 147–148, 192–193, 259, 437, 498, 536; Fisher's exact p-values and, 57–58, 60–61, 64, 67, 70, 75t, 78, 80; general causal estimands and, 464; instrumental variables analysis and, 516–517, 536, 554–556, 569, 573; labor market and, 243; matching and, 401, 415–416, 418–420, 422; model-based analysis and, 141, 147–150, 158, 162, 164t, 167, 176, 181, 569, 573; notation and, 27–28; pairwise randomized experiments and, 223–224, 225t, 229, 232–233; potential outcomes and, 23–24, 27–29; real world and, 7–8; regression analysis and, 113–114, 116, 118–119, 122, 127, 132; sampling variances and, 433–434, 437, 441, 450, 453, 460; sensitivity analysis and, 498; stratified randomized experiments and, 192–193, 195–197; SUTVA and, 13; unconfoundedness and, 259–261, 482
- ordinary least squares (OLS) estimators: instrumental variables analysis and, 534, 558; matching and, 404, 418, 428; model-based analysis and, 173; potential outcomes and, 28; propensity score and, 389; regression analysis and, 113, 118, 127, 135; stratified randomized experiments and, 205
- outliers: Fisher's exact p-values and, 65–67, 72–73; general causal estimands and, 466; Neyman's

- outliers (*cont.*)  
 repeated sampling approach and, 98; pairwise randomized experiments and, 223–224; stratified randomized experiments and, 198
- overlap: ability to adjust for differences and, 317–318; *a priori* approach and, 313, 325, 326, 336; assignment mechanisms and, 314–316; assumptions and, 309, 314, 332; balance and, 309–333, 336; barbiturate data and, 319–322; bias and, 309, 311, 318, 325, 331; causal effects and, 309, 317–318, 321, 327–333, 336; causal estimands and, 336; completely randomized experiments and, 318; conditional distribution and, 314, 316; confidence intervals and, 335–336; control distribution and, 312–313; control units and, 309, 311–313, 319, 321; covariance matrices and, 314; covariates and, 309–336; dispersion and, 310, 312, 314, 321; drug treatment and, 319, 320t; empirical distribution and, 312–313; estimators and, 314, 336; imputation and, 309; individualistic assignment and, 316; lack of, 332–336; Lalonde experimental data and, 326–327; Lalonde non-experimental data and, 328–333; lotteries and, 322–328; Mahalanobis metric and, 314; marginal distribution and, 314, 316; matching and, 309, 321, 336; model-based analysis and, 309, 336; National Supported Work (NSW) job-training data and, 324f, 328, 330–335; normal distribution and, 323f–325f; normalized difference and, 310–315, 318, 325, 327; null hypothesis and, 311; observation and, 310–312, 318; populations and, 309–317, 321, 325, 328, 332–333; post-treatment variables and, 325; potential outcomes and, 312–313, 334; pre-treatment variables and, 313, 319, 326–327, 330; propensity score and, 309–310, 314–334; randomized experiments and, 309, 312, 318, 328, 332; regression analysis and, 309, 311, 325, 331, 332–337; Reinisch barbiturate exposure data and, 318–322, 325t; robustness and, 310, 317; samples and, 309–319, 325, 326, 329, 333, 336; standard deviation and, 312–313, 315, 318–321, 331; subclassification and, 309, 336; subpopulations and, 310, 316, 321, 333; subsamples and, 309–312, 326, 332, 336; test statistics and, 311, 366; treatments and, 309–311, 313–322, 325–336; unconfoundedness and, 309–310, 314, 316, 321, 332; z-values and, 321
- pairwise randomized experiments: *a priori* approach and, 219; assignment mechanisms and, 41, 221, 223, 232; assumptions and, 226, Bayesian approach and, 232–233; bias and, 225–227, 229, 234; Children's Television Workshop and, 220–228, 231, 233t, 234; classical randomized experiments and, 47–48, 52–55; completely randomized experiments and, 219, 223, 225–226, 228, 232, 234; control units and, 221, 223–224, 225t, 229, 233; covariance matrices and, 239; covariates and, 219–222, 229–233; estimators and, 219, 224–227, 229–231, 233–234, 236, 239, 457–459; finite samples and, 222, 226, 232; Fisher's exact p-values and, 220, 222–224, 233; imputation and, 220, 231; joint distribution and, 231–232; least squares estimators and, 230–231; matching and, 219, 234, 402, 406–407, 409–410, 425; model-based analysis and, 220, 231–234; Neyman's repeated sampling approach and, 219–220, 224–228, 233; notation and, 220–221; null hypothesis and, 223–224; observed outcomes and, 223, 225t, 229, 232–233; outliers and, 223–224; populations and, 219–220, 229–232; posterior distribution and, 232–233; potential outcomes and, 219–224, 228–232; pre-treatment variables and, 221, 233; randomization distribution and, 223, 225–226, 229–230; regression analysis and, 220, 229–234, 240–241, 247–249, 253–254; sampling variances and, 219, 225–228, 233–235, 457–459; simulation and, 232–233; standard deviation and, 233; stratified randomized experiments and, 212, 219–221, 226, 229, 231, 233–234; super-populations and, 230, 232; treatments and, 219–235; unconfoundedness and, 255–265, 271, 276, 279
- Panel Study of Income Dynamics (PSID), 329, 495
- partial equilibrium, 11
- partial identification approach. *See* bounds
- path diagrams, 22
- per protocol analysis, 514, 535–540
- placebos, 11–12, 49, 115–116, 131, 528
- populations, 40, 589; assignment mechanisms and, 13, 33–35, 39–41; average treatment effect and, 98–101, 454–455; causal estimands and, 18–19; classical randomized experiments and, 51, 55; covariates and, 20–21 (*see also* covariates); Fisher exact p-values and, 61, 72; frequentist perspective and, 172–174; general causal estimands and, 465–467, 473–474; instrumental variables analysis and, 515, 518, 520–542, 545–547, 550–556, 559–568, 578; labor market and, 240, 245–247; matching and, 338, 346, 407–408, 415–416, 426–427, 431; model-based analysis and, 141–146, 171–173, 181, 185, 560–568, 578; Neyman's repeated sampling approach and, 83–86, 89–90, 92–94, 97–102, 105–106, normalized difference and, 310–315, 318, 325, 327, 339, 350, 352, 354, 356f, 358, 361–362, 368, 370, 378–379, 386, 399, 404, 428, 435, 462; observed value and, 21; overlap and, 309–317, 321, 325, 328, 332–333; pairwise randomized experiments and, 219–220, 229–232; propensity score and, 282, 291, 298, 307, 377, 383, 387, 392, 400; regression analysis and, 113–126, 130–131, 135–136, 139; sampling variances and, 433–434, 436–441, 445–448, 454–455, 459; sensitivity analysis and, 497–500, 503; stratified randomized experiments and, 191, 193, 201–207, 211–216; subpopulations and, 16 (*see also* subpopulations); super-populations and, 20–21, 39–40, 83, 93, 98–99, 101, 105–106, 110n2, 113–120, 122, 124; treatments and, 15–16 (*see also* treatments); trimming and, 359–360, 362–363, 365–366; unconfoundedness and, 257, 259–263, 266, 268–274, 277–278, 479, 482, 485, 487–489, 493t–494t, 495
- posterior distribution: causal estimand and, 155–156; derivation of, 154–155, 160–163; general causal estimands and, 467, 469, 472–473; instrumental variables analysis and, 561, 566, 570, 572–583; labor market and, 250–251, 253; likelihood

- functions and, 178; missing outcomes and, 155, 160–161; model-based analysis and, 144, 151–155, 158–163, 166–167, 170–172, 176–180, 183, 185, 561, 566, 570, 572–583; pairwise randomized experiments and, 232–233; stratified randomized experiments and, 207–210
- post-treatment variables, 6, 14, 17; Fisher exact p-values and, 80; matching and, 415; Neyman's repeated sampling approach and, 85t, 103t; overlap and, 325; regression analysis and, 116, 131
- potential outcomes, xvii–xviii, 589–590; action-unit pair and, 4; a priori approach and, 25; assignment mechanisms and, 23–24, 27–40; assumptions and, 25–26; attributes and, 29; basics of, 3–22; bias and, 25–26; causal effects and, 14, 23–30; causal estimands and, 25, 468–472; causal language and, 3–4; classical randomized experiments and, 47, 50–52, 55–56; completely randomized experiments and, 25–26; compliance status and, 524–526; control units and, 29–30; covariates and, 27–28; dependence between, 165–169; drug treatment and, 12–16; earlier hints for physical randomizing and, 26; early uses of in social sciences, 28–29; estimated associations and, 27–28; Fisher exact p-values and, 17, 26–27, 57–80, 83; general causal estimands and, 461–474; instrumental variables analysis and, 513, 516–517, 520, 522–525, 528, 530, 532–534, 539–540, 545–546, 549, 553–554, 557, 559–560, 563–583; joint distribution and, 96 (*see also* joint distribution); labor market and, 250, 253; least squares estimators and, 28; Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) and, 115–116, 131–133; Lord's paradox and, 16–18, 22, 28; matching and, 338, 343, 401–402, 404, 407, 409, 412, 415–417, 419, 421; model-based analysis and, 141–157, 160, 163–177, 181–182, 185, 560, 563–583; multiple block, 469, 472; Neyman's repeated sampling approach and, 83–96, 99–100, 106, 108; notation and, 23–30; observation and, 3–4, 12, 23, 27–30; observed outcomes and, 23–24, 27–28, 29; observed value and, 27–28, 30; overlap and, 312–313, 334; pairwise randomized experiments and, 219–224, 228–232; propensity score and, 378, 382–384, 392, 395–396, 399; Randomized Blocks and Latin Squares and, 27; randomized experiments and, 23–30; random variables and, 3, 25; regression analysis and, 28, 30, 113–114, 116–117, 119–121, 124–130; samples and, 25–26; sampling variances and, 433–434, 445–446, 448, 450, 457; sensitivity analysis and, 496–505; simulation methods and, 163–165; single block, 468–469; stable unit treatment value assumption (SUTVA) and, 9–15, 21–22, 25, 33; statistical model and, 27, 29; stochastic treatments and, 25; stratified randomized experiments and, 192, 195, 199–200, 202, 204, 207–210, 212, 214; subpopulations and, 190; treatments and, 24–30; trimming and, 366; unconfoundedness and, 257–272, 479–483, 487, 489
- pre-treatment variables, 589; assignment mechanisms and, 32–33, 42; attributes and, 15–16; causal estimands and, 21; classical randomized experiments and, 52–53, 55; conditioning and, 265–266; Fisher exact p-values and, 57, 64, 78–79, 81; general causal estimands and, 461, 468; instrumental variables analysis and, 527, 538, 546–547, 561, 567; labor market and, 241t, 242, 247–249; matching and, 338, 401–402, 405, 411, 415–416, 418, 424; model-based analysis and, 142, 561, 567; Neyman's repeated sampling approach and, 85t, 102, 103t; overlap and, 313, 319, 326–327, 330; pairwise randomized experiments and, 221, 233; propensity score and, 281–286, 294; regression analysis and, 113, 115–117, 122, 134; robustness and, 487–490; sampling variances and, 433–435, 437–438, 440–443, 446, 451, 453–454, 456, 460; stratified randomized experiments and, 187, 189; subpopulations and, 18; trimming and, 359–362, 368, 370; unconfoundedness and, 257–266, 279, 479–484, 487–492, 494
- principal stratification, 43, 134, 514, 590
- prior distribution: general causal estimands and, 468, 472; instrumental variables analysis and, 565–567, 572–573, 576–577, 579–582; labor market and, 250; likelihood functions and, 178; model-based analysis and, 143–144, 152, 154–156, 158–160, 163, 166–167, 170–172, 174–176, 178–183, 185, 566–567, 572–573, 576–577, 579–582; stratified randomized experiments and, 208–210, 232–233
- probabilistic assignment: classical randomized experiments and, 48; definition of, 31, 38; propensity score and, 48; as restriction, 38, 40, 43; sensitivity analysis and, 496; strongly ignorable treatment assignment and, 39; super-populations and, 40; unconfoundedness and, 257–258, 261–262, 269, 280
- Project Star, 188–189, 190t, 197–199, 201, 203, 204t, 207–209, 212
- propensity score, 590; additional linear terms and, 287; a priori approach and, 281, 286, 399; assignment mechanisms and, 35–40, 377, 380; assignment probabilities and, 282; assumptions and, 282, 284, 377–378, 383, 397–398; attributes and, 385; average treatment effect and, 378, 382–383, 386–399; balance and, 258, 265–268, 273, 282–284, 286, 294–307, 314–317, 377–382, 385, 387, 396, 399; balancing scores and, 266–268; Bayesian approach and, 306; bias and, 281, 283, 285, 306, 377–378, 380–389, 392, 395, 397t, 398–399; blocking and, 293–294, 377–378, 382–383, 387, 394–396, 400; causal effects and, 281, 284–285, 297–298, 302, 306–307, 377–378, 382, 387, 392; classical randomized experiments and, 48–53; completely randomized experiments and, 282, 378, 387–388, 390; conditional mean and, 302, 316; control units and, 282, 292–293, 302, 377, 380–385, 399; covariates and, 282–308, 377–387, 390–399; dispersion and, 394; drug treatment and, 285t, 289t, 290, 291t, 301t, 304t–305t; estimated, 274–278, 281–308, 315, 317, 320, 326–327, 331, 338, 341–344, 349–350, 356–357, 360, 367–369, 372–374, 377–382, 387, 392–395, 405, 409, 432, 435, 443–444, 462, 494, 506; estimators and, 273–275, 281, 297, 307, 378–384, 386–400; finite population, 35–37; Fisher's exact p-values

- propensity score (*cont.*)  
 and, 297; general causal estimands and, 462–463, 469; imputation and, 378, 387; interactions and, 285–288; kernel smoothing and, 306; labor market and, 254; lasso method for, 303–306; least squares estimators and, 387–393, 397–398; likelihood and, 284–290, 306–308; lotteries and, 281, 307, 378–381, 385–386, 390–392, 395–399; matching and, 337–359, 361, 374, 383, 404–405, 409–410, 416–417, 431–432; Neyman's repeated sampling approach and, 297, 377, 388–390; normal distribution and, 293, 298–303, 306t, 308; normalized difference and, 378–379, 386, 399; notation and, 282, 381; null hypothesis and, 285, 287–288, 295, 298–302, 381–382, 385; observation and, 294–295, 387, 391, 396; overlap and, 309–310, 314–334; populations and, 282, 291, 298, 307, 377, 383, 387, 392, 400; potential outcomes and, 378, 382–384, 392, 395–396, 399; pre-treatment variables and, 281–286, 294; probabilistic assignment and, 48; pseudo-outcomes and, 297–298; quadratic terms and, 287–288; randomized experiments and, 281–282, 297, 378, 381, 387–388; regression analysis and, 284, 286–288, 298, 306–308, 378, 384–385, 387–399; regular assignment mechanisms and, 377; Reinisch barbiturate exposure data and, 284–290, 294–296, 300–306; residuals and, 299, 397t; robustness and, 308, 378, 389–390, 393–395, 400; samples and, 282–285, 292–293, 295, 297–298, 300, 303, 377–399; sampling variances and, 297–298, 388–390, 395–399, 435, 442–444, 460; sensitivity analysis and, 498, 506–507; simulation and, 400; specification choice and, 288–290; split blocks and, 294; standard deviation and, 285, 386, 396, 398; strata construction and, 290–295; stratified randomized experiments and, 191, 297, 381, 388; subclassification and, 295, 377–400; subpopulations and, 298, 377; subsamples and, 277–278, 282, 285, 292–293, 295, 366–368, 379, 389–390, 417, 421, 428; super-populations and, 39–40, 282, 291, 307; test statistics and, 285, 287, 293–295, 300–302, 381–382, 385; treatments and, 281–286, 291–299, 302, 307, 377–378, 381–399; trimming and, 359–374, 377–400; true, 277, 281–283, 291–292, 306–307, 314–317, 326, 337, 343, 359, 381, 387, 395, 399, 442; unconfoundedness and, 258–259, 266–270, 273–282, 284, 377, 392, 399, 491, 494; weighting and, 270, 273–275, 281–282, 378, 392–399; z-values and, 298–303, 304t–305t, 306f
- pseudo-outcomes: estimating effects on, 482–485; Neyman's repeated sampling approach and, 102; propensity score and, 297–298; testing for effects on, 490–492; unconfoundedness and, 480–485, 487, 490–493, 495
- pseudo treatments:: estimating effects of, 485–486; testing for effects of, 493; unconfoundedness and, 278–279, 480–482, 485–486, 493
- randomized encouragement design, 540, 560
- randomization distribution: instrumental variables analysis and, 520–521; labor market and, 243t, 249; Neyman's repeated sampling approach and, 83–84, 86–88, 96, 99–100, 102, 106–107; pairwise randomized experiments and, 223, 225–226, 229–230; regression analysis and, 117; sampling variances and, 436–437; sensitivity analysis and, 507; stratified randomized experiments and, 193–194, 197–198, 200–201, 214; unconfoundedness and, 273
- Randomized Blocks and Latin Squares method, 27
- randomized consent design, 540, 560
- randomized encouragement designs, 540
- randomized experiments, 40; assignment mechanisms and, 31–32, 35–36, 40–43; causality and, 3; classical, 20, 31–32, 40 (*see also* classical randomized experiments); completely, 21, 25–26, 41, 47–48, 50–82 (*see also* completely randomized experiments); design stage and, 32; earlier hints for physical randomizing and, 26; Fisher exact p-values and, 26–27, 57–82; general causal estimands and, 467; labor market and, 241, 253; matching and, 337, 341, 343, 349, 352, 402–403, 407, 409; model-based analysis and, 141–186; Neyman's repeated sampling approach and, 83–112 (*see also* Neyman's repeated sampling approach); one-sided compliance and, 513–541; overlap and, 309, 312, 318, 328, 332; paired, 53; pairwise, 219–239 (*see also* pairwise randomized experiments); pharmaceutical approvals and, 40; potential outcomes and, 23–30; propensity score and, 281–282, 297, 378, 381, 387–388; regression analysis and, 113–140; sampling variances and, 436, 457; sensitivity analysis and, 503, 507; stratified, 52, 187–218 (*see also* stratified randomized experiments); two-sided compliance and, 542–584; unbalanced, 32; unconfoundedness and, 257, 259, 264, 267, 270–275, 279
- random variables, 3; Fisher exact p-values and, 72; model-based analysis and, 141, 144, 151, 173, 179–180, 182; Neyman's repeated sampling approach and, 88, potential outcomes and, 3, 25; regression analysis and, 118–119; unconfoundedness and, 271
- regression analysis: assignment mechanisms and, 43; assumptions and, 113, 115–116, 118–122, 126, 128, 130, 133–134; asymptotic distribution and, 114, 135; balance and, 134; bias and, 113–114, 118–119, 122, 124–125, 128, 134; causal effects and, 113, 115, 118, 126–127, 133–134; completely randomized experiments and, 113–140; conditional mean and, 114, 117, 119, 133, 162, 176, 272, 302, 316, 346, 417, 450, 532; confidence intervals and, 120, 134; control functions and, 247, 419–420, 422t–423t, 427, 432; control units and, 127; covariance matrices and, 117, 122, 130, 135–136, 138–140; covariates and, 114–134; drug treatment and, 115–116, 131–132, 134; estimators and, 113–114, 118–122, 124–128, 130, 132, 134–135, 137; finite samples and, 113–114, 117–118, 122, 124–125, 128; Fisher's exact p-values and, 79–82, 129–130, 133t; Freedman and, 113–114; full distribution and, 114, 165, 317; general causal estimands and, 461–463, 468; heteroskedasticity and, 121, 125, 389, 450, 453t; homoskedasticity and, 120–121, 125, 196,

- 234, 341, 366–367, 398, 426, 452, 453t;  
 imputation and, 113, 126–127; instrumental  
 variables analysis and, 532–534, 557–558,  
 565–566, 578; intention-to-treat (ITT) effects  
 and, 131; interactions and, 125–127; joint  
 distribution and, 116; labor market and,  
 247–249; least squares estimators and, 113–114,  
 118–130, 134–135; limiting objective function  
 and, 123; limits on increases in precision and,  
 128–129; linear, 113–114, 118–128, 131, 134,  
 142, 173, 175, 179, 248–249, 263, 272, 298,  
 309, 332–334, 336–337, 346, 378, 387–390,  
 417, 431–432, 494, 533; Lipid Research Clinics  
 Coronary Primary Prevention Trial  
 (LRC-CPPT) and, 115–116, 131–133; logistic,  
 128, 177t, 180, 283–288, 307–308, 343, 380,  
 468, 504, 565–566, 571, 578; matching and,  
 346, 404, 416–424, 427–428, 430–432;  
 model-based analysis and, 114, 134, 141–142,  
 173, 175, 179–180, 565–566, 578; Neyman's  
 repeated sampling approach and, 113–114, 121,  
 134, 141; normal distribution and, 139; notation  
 and, 114, 117, 119, 122; null hypothesis and,  
 130–133, 139; observation and, 113, 118, 125,  
 127–129, 134; observed outcomes and,  
 113–114, 116, 118–119, 122, 127, 132; overlap  
 and, 309, 311, 325, 331, 332–337; pairwise  
 randomized experiments and, 229–234,  
 240–241, 247–249, 253–254; parallel, 420;  
 populations and, 113–126, 130–131, 135–136,  
 139; post-treatment variables and, 116, 131;  
 potential outcomes and, 28, 30, 113–114,  
 116–117, 119–121, 124–130; pre-treatment  
 variables and, 113, 115–117, 122, 134; probit,  
 128, 308; propensity score and, 284, 286–288,  
 298, 306–308, 378, 384–385, 387–399;  
 randomization distribution and, 117; random  
 variables and, 118–119; residuals and, 118–121;  
 robustness and, 121, 125, 127; samples and,  
 113–139; sampling variances and, 113,  
 120–121, 124–125, 128–129, 434–436,  
 442–444, 450, 453t, 456; sensitivity analysis  
 and, 504; simulation methods and, 179–180;  
 statistical model and, 114, 128; stochastic  
 treatments and, 116; stratified randomized  
 experiments and, 187–189, 205–207, 213–214,  
 217; subpopulations and, 131;  
 super-populations and, 113–114, 116–120, 122,  
 124, 126; SUTVA violations and, 188; test  
 statistics and, 133; transformations of outcome  
 variable and, 127–128; treatments and,  
 113–134; trimming and, 362; unconfoundedness  
 and, 263, 272–274, 276–277, 280, 494  
 regression discontinuity designs, 43–44, 590  
 regular assignment mechanisms, 20, 32, 589;  
 implications of, 258–260; individualistic factor  
 and, 258–259; model-based analysis and, 153,  
 567; observation and, 41–43; propensity score  
 and, 377; sampling variances and, 437;  
 sensitivity analysis and, 496; super-population  
 perspective and, 260–261; unconfoundedness  
 and, 258–266, 276, 279, 479  
 Reinisch barbiturate exposure data: matching and,  
 338–339, 340t, 344, 345t, 349–358; overlap and,  
 319–322, 323t, 325t; propensity score and,  
 284–290, 294–296, 300–306  
 residuals: definition of, 119; Fisher's exact p-values  
 and, 82; instrumental variables analysis and,  
 532–533, 556–558; matching and, 418;  
 propensity score and, 299, 397t; regression  
 analysis and, 118–121; sampling variances and,  
 450  
 right heart catheterization, 360–362, 368–373  
 robustness, 589; Fisher's exact p-values and, 66;  
 general causal estimands and, 466; instrumental  
 variables analysis and, 578; matching and,  
 337–338, 341, 349, 430–432; model-based  
 analysis and, 142, 152, 156, 578; overlap and,  
 310, 317; pre-treatment variables and, 487–490;  
 propensity score and, 308, 378, 389–390,  
 393–395, 400; regression analysis and, 121, 125,  
 127; trimming and, 362, 365, 370;  
 unconfoundedness and, 260, 270, 274–277,  
 481–482, 487–490, 494–495  
 R-programs, 280  
 Rubin Causal Model, 21, 540, 589  
 Sacerdote lottery data, 322, 378–379, 434–436, 444t,  
 449, 451t, 453t, 457t, 482–483, 488, 491t–494t,  
 497  
 samples: assignment mechanisms and, 31–32, 39–40;  
 classical randomized experiments and, 50,  
 52–54, 56; covariate balance and, 277, 282,  
 300–306, 309, 316–318, 329, 336–337, 359, 380,  
 428–429; finite, 18 (*see also* finite samples);  
 Fisher exact p-values and, 57, 59, 62–63, 66–72,  
 76–77, 81; full, 52, 59, 81, 85, 242–246, 277,  
 337, 344, 349–352, 358–361, 368–373, 378–380,  
 383–387, 391, 395–399, 401, 404, 417, 425,  
 427–428, 435, 444, 452, 462, 490, 494; general  
 causal estimands and, 462, 464–474;  
 instrumental variables analysis and, 516–523,  
 527–528, 530–532, 535, 537, 541, 544, 546–548,  
 555, 561, 563, 572, 575, 578–583; labor market  
 and, 240, 242–243, 245–247, 250, 253; matching  
 and, 337–358, 401–421, 424–431; model-based  
 analysis and, 141–142, 144–145, 162–163, 169,  
 171–174, 178, 180–181, 184–186, 561, 563, 572,  
 575, 578–583; Neyman's repeated sampling  
 approach and, 83–112 (*see also* Neyman's  
 repeated sampling approach); overlap and,  
 309–319, 323, 326, 329, 332, 336; pairwise  
 randomized experiments and, 219–220, 222,  
 224–230, 232–235; populations and, 20–21 (*see  
 also* populations); potential outcomes and,  
 25–26; propensity score and, 282–285, 292–293,  
 295, 297–298, 300, 303, 377–399; regression  
 analysis and, 113–139; stratified randomized  
 experiments and, 187–190, 193–194, 196–197,  
 200–207, 211–213, 217–218; subsamples and,  
 366–368 (*see also* subsamples); trimming and,  
 359–374; unconfoundedness and, 257–262,  
 268–279, 490–494, 497–499, 501–502, 505,  
 508–509  
 sampling variances: affine consistency and, 434,  
 441–444; alternative estimators for, 456–460;  
 assignment mechanisms and, 437; assumptions  
 and, 437, 452; asymptotic distribution and, 447;  
 average treatment effects and, 433–445,  
 450–460; Bayesian approach and, 434; bias and,  
 434, 436, 438–439, 445–448, 450–451, 457–459;



- sampling variances: affine consistency and (*cont.*)  
 blocking and, 434–435, 444t, 453t; bootstrap  
 methods and, 434, 453t, 456, 459–460; causal  
 effects and, 433–440; classical randomized  
 experiments and, 56; conditional, 434, 445–452;  
 confidence intervals and, 84, 87, 92–96,  
 102–103, 433, 460; control units and, 433–434,  
 441–443, 447–448, 451, 453, 459–460;  
 covariates and, 434–437, 440–452, 456, 460;  
 dispersion and, 466–467; estimand choice and,  
 433–434, 436–441; estimation of, 92–95;  
 estimators and, 121, 433–460; imputation and,  
 434, 451; instrumental variables analysis and,  
 520–521, 530–531, 541, 547–548; interval  
 estimators and, 436; joint distribution and, 434,  
 467; labor market and, 245–246; least squares  
 and, 435–436, 442, 444, 456–460; lotteries and,  
 434–436, 443–445, 449–459; Mahalanobis  
 metric and, 448; matching and, 341, 402–403,  
 407, 409, 424, 426, 428, 431, 434–436, 443–444,  
 446–447, 449–450, 452–460; model-based  
 analysis and, 172, 450; Neyman's repeated  
 sampling approach and, 84, 87–104, 105–109,  
 438–439; normalized difference and, 435;  
 notation and, 445; observation and, 449t, 465;  
 observed outcomes and, 433–434, 437, 441, 450,  
 453, 460; pairwise randomized experiments and,  
 219, 225–228, 233–235, 457–459; populations  
 and, 433–434, 436–441, 445–448, 454–455, 459;  
 potential outcomes and, 433–434, 445–446, 448,  
 450, 457; pre-treatment variables and, 433–435,  
 437–438, 440–443, 446, 451, 453–454, 456, 460;  
 propensity score and, 297–298, 388–390,  
 395–399, 435, 442–444, 460; quantile treatments  
 and, 465–466, 473–474; randomization  
 distribution and, 436–437; regression analysis  
 and, 113, 120–121, 124–125, 128–129, 434–436,  
 442–444, 450, 453t, 456; regular assignment  
 mechanisms and, 437; residuals and, 450;  
 sensitivity analysis and, 498; standard deviation  
 and, 435, 444, 451; stratified randomized  
 experiments and, 193–194, 196, 201–204,  
 206–207, 211–213, 217–218; subclassification  
 and, 443–444, 451–452, 456–457, 460;  
 subpopulations and, 436, 438–439, 445;  
 subsamples and, 434–438, 459–460;  
 super-populations and, 433–441, 445–448;  
 treatments and, 433–447, 450–460; trimming  
 and, 360, 363–377, 451; unconfoundedness and,  
 268–270, 437, 445; weighting and, 441–445,  
 442–444
- Saturation Work Initiative Model (SWIM), 240–242,  
 243t, 250, 253
- semi-design approach, 279, 481, 485, 493
- semiparametric efficiency bound, 268–270, 280
- sensitivity analysis: *a priori* approach and, 501;  
 assignment mechanisms and, 496, 499, 507;  
 assignment probabilities and, 506–507, 509;  
 assumptions and, 496–500, 503–506, 509;  
 average treatment effect and, 508; bias and,  
 497–504; binary outcomes and, 500–508; bounds  
 and, 496–509, 513; causal effects and, 496;  
 causal estimands and, 496; completely  
 randomized experiments and, 498, 503, 507;  
 control units and, 498; Cornfield–Rosenbaum–  
 Rubin approach and, 496–497, 500–506,  
 508–509; covariates and, 496–509; estimable  
 parameters and, 501–502; estimators and, 497;  
 Fisher's exact p-values and, 506; lotteries and,  
 497–498, 500, 504–508; Neyman's repeated  
 sampling approach and, 498; notation and, 503;  
 null hypothesis and, 500, 506–507; observation  
 and, 496, 506; observed outcomes and, 498;  
 observed value and, 509; overlap and, 332–336;  
 partial identification approach and, 496;  
 populations and, 497–500, 503; potential  
 outcomes and, 496–505; probabilistic assignment  
 and, 496; propensity score and, 498, 506–507;  
 randomization distribution and, 507; randomized  
 experiments and, 503, 507; regression analysis  
 and, 504; regular assignment mechanisms and,  
 496; Rosenbaum p-value, 506–508; sampling  
 variances and, 498, 498; sharp null hypothesis  
 and, 506; stable unit treatment value assumption  
 (SUTVA) and, 498; standard deviation and,  
 504–505, 508; subclassification and, 497;  
 super-populations and, 497–500, 503; treatments  
 and, 496–509; unconfoundedness and, 279,  
 496–500, 503–504, 506–507, 509
- Sesame Street* (TV series), 220
- sharp null hypothesis: as exact null hypothesis, 57;  
 Fisher's exact p-values and, 57–83, 93, 189, 192,  
 195, 240, 337; matching and, 337; sensitivity  
 analysis and, 506
- simulation: Fisher's exact p-values and, 58, 72–74,  
 77t; instrumental variables analysis and, 561,  
 566, 572, 574–577; labor market and, 250;  
 logistic regression model and, 180; matching  
 and, 432, 434, 460; model-based analysis and,  
 142–144, 152, 163–165, 171, 176–180, 561, 566,  
 572, 574–577; pairwise randomized experiments  
 and, 232–233; propensity score and, 400
- stable unit treatment value assumption (SUTVA):  
 alternatives to, 12–13; basic framework of causal  
 inference and, 3, 9–15, 21–22; drug treatment  
 and, 12–15; exclusion restrictions and, 10–13;  
 instrumental variables analysis and, 514,  
 516–517, 550, 589–590; Lord's paradox and,  
 17–18; model-based analysis and, 589–590;  
 Neyman's repeated sampling approach and, 84;  
 no hidden variations, 11–12; no interference,  
 10–11; null hypothesis and, 22; potential  
 outcomes and, 25, 33; sensitivity analysis and,  
 498; stratified randomized experiments and, 199;  
 surgery and, 14–15; treatments and, 9–15,  
 21–22, 25, 33, 84, 188–189, 199, 498, 514,  
 516–517, 550, 589–590
- standard deviation: general causal estimands and, 466,  
 472; instrumental variables analysis and, 561,  
 582; labor market and, 242, 250–253; matching  
 and, 339, 350, 356; model-based analysis and,  
 149–150, 155, 163, 165, 169, 172, 174–177, 561,  
 581–582; Neyman's repeated sampling approach  
 and, 85; overlap and, 312–313, 315, 318–321,  
 331; pairwise randomized experiments and, 233;  
 propensity score and, 285, 386, 396, 398;  
 sampling variances and, 435, 444, 451;  
 sensitivity analysis and, 504–505, 508; stratified  
 randomized experiments and, 189, 209–210;  
 trimming and, 361, 370; unconfoundedness and,  
 277
- STATA programs, 280, 431–432

- statistic, 64
- statistical model: general causal estimands and, 472;
  - instrumental variables analysis and, 560, 581;
  - model-based analysis and, 142, 173–174, 177, 560, 581; potential outcomes and, 27, 29;
  - regression analysis and, 114, 128
- statistical power, 58, 64, 80
- stochastic treatments, 12; Fisher's exact p-values and, 57–58; instrumental variables analysis and, 526–527, 551, 553, 568, 577; model-based analysis and, 141–142, 162, 568, 577; Neyman's repeated sampling approach and, 84, 99; potential outcomes and, 25; regression analysis and, 116; stratified randomized experiments and, 208
- stratified randomized experiments: *a priori* approach and, 197, 208; assignment mechanisms and, 41–42, 191–192, 201–202; asymptotic distribution and, 216; balance and, 191–193; Bayesian approach and, 213; benefits of, 187; bias and, 187, 201–204, 206, 211–212, 217; causal effects and, 195, 206; causal estimands and, 208; classical randomized experiments and, 47–48, 51–55; completely randomized experiments and, 187–195, 197, 201, 204, 207, 211–212; confidence intervals and, 187, 203–204, 227–228; covariance matrices and, 216–217; covariates and, 187, 190–191, 195; design issues in, 211–212; dispersion and, 189, 198; estimators and, 201–207, 211–212, 216; finite samples and, 190, 201; Fisher's exact p-values and, 192–201; imputation and, 187–189, 209; interval estimators and, 213; joint distribution and, 207–208; *J* strata case and, 192, 196–197; least squares estimators and, 205–207, 214; model-based analysis and, 207–212; Neyman's repeated sampling approach and, 201–205, 213; notation and, 190, 192, 199, 205, 209; null hypothesis and, 189, 192–193, 195–201, 214; observation and, 187, 206; observed outcomes and, 192–193, 195–197; outliers and, 198; pairwise randomized experiments and, 212, 219–221, 226, 229, 231, 233–234; populations and, 191, 193, 201–207, 211–216; posterior distribution and, 207–210; potential outcomes and, 192, 195, 199–200, 202, 204, 207–210, 212, 214; pre-treatment variables and, 187, 189; prior distribution and, 208–210, 232–233; Project Star and, 188–189, 190t, 197–199, 201, 203, 204t, 207–209, 212; propensity score and, 190, 192, 205, 297, 381, 388; randomization distribution and, 193–194, 197–198, 200–201, 214; regression analysis and, 187–189, 205–207, 213–214, 217; samples and, 190, 193–194, 196–197, 200–207, 211–213, 217–218; sampling variances and, 193–194, 196, 201–204, 206–207, 211–213, 217–218; stable unit treatment value assumption (SUTVA) and, 188–189, 199; standard deviation and, 189, 209–210; stochastic treatments and, 208; structure of, 189–192; subpopulations and, 190, 211; subsamples and, 190–191, 211; super-populations and, 205, 211; test statistics and, 193–195, 197–200; treatments and, 187–198, 201–207, 210–213; two strata case and, 189–196; unconfoundedness and, 259, 275, 279; weighting and, 194
- strongly ignorable treatment assignment, 39, 43, 280
- subclassification: average treatment effect and, 382–383; bias reduction and, 380–388; blocking and, 270 (*see also* blocking); estimators and, 382–384, 388, 394–399, 443–444, 452, 456–457, 460, 497; general causal estimands and, 464t; least squares and, 456–460; lotteries and, 385–386, 390–392; overlap and, 309, 336; propensity score and, 295, 377–400; sampling variances and, 443–444, 451–452, 456–457, 460; sensitivity analysis and, 497; unconfoundedness and, 270, 273–276, 490, 494; weighting estimators and, 392–399
- subpopulations: assignment mechanisms and, 20, 35; finite samples and, 18; homogeneity and, 16; instrumental variables analysis and, 515, 523–525, 529–530, 538–539, 542, 547, 550, 554–555, 559–560, 565, 578; labor market and, 240, 245–246; matching and, 338, 427, 431; model-based analysis and, 560, 565, 578; Neyman's repeated sampling approach and, 102; overlap and, 310, 316, 322, 333; potential outcomes and, 190; propensity score and, 298, 377; regression analysis and, 131; sampling variances and, 436, 438–439, 445; stratified randomized experiments and, 191, 211; trimming and, 359, 363, 365; unconfoundedness and, 257, 259, 262, 270, 277–278, 482, 485, 487, 489, 493t–494t
- subsamples: Fisher's exact p-values and, 59, 66, general causal estimands and, 462, 472–473; instrumental variables analysis and, 518, 527, 541, 561; labor market and, 242–243, 245; matching and, 339–344, 350; model-based analysis and, 561; Neyman's repeated sampling approach and, 101–102; overlap and, 309–312, 326, 332, 336; propensity score and, 277–278, 282, 285, 292–293, 295, 366–368, 379, 389–390, 417, 420, 428; sampling variances and, 434–438, 459–460; stratified randomized experiments and, 190–191; trimming and, 359, 362, 365–373; unconfoundedness and, 257–259, 276–277, 493
- super-populations: assignment mechanisms and, 39–40; average treatment effects and, 116–117; compliance status and, 525–526; general causal estimands and, 465, 473–474; instrumental variables analysis and, 520–521, 525–527, 531–532, 534–536, 541, 545–547, 551–553, 560, 563–564, 566–567, 578; matching and, 346, 407, 415–416, 426; model-based analysis and, 142, 144, 171–172, 181, 560, 563–564, 566–567, 578; Neyman's repeated sampling approach and, 83, 93, 98–99, 101, 109–112; overlap and, 315; pairwise randomized experiments and, 230, 232; probabilistic assignment and, 40; propensity score and, 282, 291, 307, 377, 383, 392; regression analysis and, 113–114, 116–120, 122, 124, 126; samples and, 20–21; sampling variances and, 433–441, 445–448, 455; sensitivity analysis and, 497–500, 503; stratified randomized experiments and, 205, 211; trimming and, 360, 362, 366; unconfoundedness and, 40, 260–261, 263, 266–273, 277, 479, 482, 488–489

- supporting analysis, 479, 495  
 surgery, 14–15, 219, 514  
 SUTVA *see* stable unit treatment value assumption
- Taylor series, 174
- test statistics: Fisher's exact p-values and, 57–81, 64, 66, 71, 80; Kolmogorov-Smirnov, 69–70, 81; labor market and, 242–243; Neyman's repeated sampling approach and, 97; overlap and, 311, 366; propensity score and, 285, 287, 293–295, 300–302, 381–382, 385; regression analysis and, 133; stratified randomized experiments and, 193–195, 197–200, 198
- treatments, xvii–xviii; ability to adjust for differences and, 317–318; active, 4, 8, 11, 13, 16–17, 19, 33 (*see also* active treatments); *a posteriori* approach and, 3; *a priori* approach and, 3, 16 (*see also a priori* approach); assignment mechanisms and, 31–44 (*see also* assignment mechanisms); attributes and, 15; average treatment effect and, 19, 56–57, 63, 81, 83–93, 95, 97–108, 112, 114, 116–134, 141 (*see also* average treatment effect); basics of, 3–22; bias and, 85–87 (*see also* bias); classical randomized experiments and, 47–56; control, 4 (*see also* control treatments); covariate balance and, 277, 282, 300–306, 309, 316–318, 329, 336–337, 359, 380, 428–429; estimators and, 55 (*see also* estimators); Fisher exact p-values and, 57–82; general causal estimands and, 461–469, 472–475; ignorable assignment and, 39; inference for average effects and, 98–101; instrumental variables analysis and, 513–569, 575, 577–584; labor market and, 240–250, 253; manipulation and, 3–5, 7, 21, 263, 524; matching and, 343, 345–350, 352, 358, 401–432; model-based analysis and, 141–142, 145–151, 155–156, 162–166, 168–178, 181–183, 185, 560–569, 575, 577–584; Neyman's repeated sampling approach and, 83–112; no hidden variations of, 11–12; observation and, 4, 12 (*see also* observation); overlap and, 309–311, 313–322, 325–336; pairwise randomized experiments and, 219–235; post-treatment variables and, 415 (*see also* post-treatment variables); potential outcomes and, 24–30; pre-treatment variables and, 15–16 (*see also* pre-treatment variables); propensity score and, 281–286, 291–299, 302, 307, 377–378, 381–399; pseudo, 278–279, 480–482, 485–486, 493; quantile, 465–466, 473–474; Randomized Blocks and Latin Squares and, 27; regression analysis and, 113–134; samples and, 25 (*see also* samples); sampling variances and, 433–447, 450–460; sensitivity analysis and, 496–509; stable unit treatments value assumption (SUTVA) and, 9–15, 21–22, 25, 33, 84, 188–189, 199, 498, 514, 516–517, 550, 589–590; stochastic, 12 (*see also* stochastic treatments); stratified randomized experiments and, 187–198, 201–207, 210–213; strongly ignorable treatment assignment and, 39, 43, 280; trimming and, 359–374; unbiased estimation of average effect of, 85–87; unconfoundedness and, 255 (*see also* unconfoundedness)
- trimming: *a priori* approach and, 368; assumptions and, 359, 361, 363, 367–368; asymptotic distribution and, 360, 363–367; balance and, 359–374; bias and, 360, 374; bounds and, 365; causal effects and, 359–360, 373–374; causal estimands and, 370; control units and, 360–361, 368, 371t–372t, 374; covariates and, 359–374; design phase and, 373; estimators and, 359–360, 363–366; inequality and, 367–368; internal validity and, 359, 365; joint distribution and, 359–360, 373; likelihood and, 368; lotteries and, 451; marginal distribution and, 367; model-based analysis and, 366–367, 378, 385, 387, 403; Neyman's repeated sampling approach and, 363; normalized difference and, 361–362, 368, 370; observation and, 359–361, 365, 373; populations and, 359–360, 362–363, 365–366; potential outcomes and, 366; pre-treatment variables and, 359–362, 368, 370; propensity score and, 359–374, 377–400; regression analysis and, 362; right heart catheterization and, 360–362, 368–373; robustness and, 362, 365, 370; samples and, 359–374; sampling variances and, 360, 363–377, 451; standard deviation and, 361, 370; subpopulations and, 359, 363, 365; subsamples and, 359, 362, 365–373; treatments and, 359–374; unconfoundedness and, 361
- unconfoundedness, 20, 589–590; *a priori* approach and, 257, 259, 278–279, 479–481, 488, 493; assessing, 278–279, 479–495; assignment mechanisms and, 31–32, 38–43, 255–265, 271, 276, 279; assignment probabilities and, 257–259, 273; assumptions and, 257–265, 272, 278–280, 479–492, 495; asymptotic distribution and, 269; balance and, 258, 266–269, 273, 276–278; balancing scores and, 265–268; Bayesian approach and, 271; bias and, 257, 259–260, 266–268, 270, 275, 277, 279, 479–481, 487–488, 492; blocking and, 270, 274–275, 484, 490–491; bounds and, 268–270; causal effects and, 260–264, 268, 271, 276, 278, 479–495; causal estimands and, 262–263, 276–277, 479–480, 489; classical randomized experiments and, 47–48, 53; completely randomized experiments and, 257, 259, 267, 270, 273–274; conditional distribution and, 261, 271, 479, 489; conditional independence assumption and, 260, 280, 483–487; conditional mean and, 272; conditioning and, 265–266; control units and, 257, 259–260, 263, 266–267, 269, 274–279, 479–481, 488, 494; covariates and, 257–260, 262, 265–280, 479–494; definition of, 31, 38; design approach and, 276–278, 480–483, 485, 491, 493, 495; drug treatment and, 262, 265; efficiency bounds and, 268–270; estimators and, 257, 260, 268–277; general causal estimands and, 468; group, 481, 485; implementation and, 484–490; importance of, 262–265; imputation and, 270–271, 273, 275–276; individualistic assignment and, 259, 261–262; instrumental variables analysis and, 513–516, 520–521, 525–526, 530, 534–539, 543, 547, 567, 572, 584; interpretation and, 483–484, 486; joint distribution and, 260–261, 270–271, 275; latent, 514, 526; least squares estimators and, 272;

- lotteries and, 482–483, 488, 490–495; marginal distribution and, 269–270; matching and, 270, 273, 275–277, 341, 346, 361, 401–402, 404, 407, 409, 484; model-based analysis and, 270–271, 275–276, 484, 567, 572–574, 578, 584; Neyman's repeated sampling approach and, 259; notation and, 260, 268, 483, 485; null hypothesis and, 278, 480–481, 485–486, 495; observation and, 257–258, 262, 264, 276, 280, 488; observed outcomes and, 259–261, 482; overlap and, 309–310, 314, 316, 321, 332; populations and, 257, 259–263, 266, 268–274, 277–278, 479, 482, 485, 487–489, 493t–494t, 495; potential outcomes and, 257–272, 479–483, 487, 489; pre-treatment variables and, 257–266, 279, 479–484, 487–492, 494; probabilistic assignment and, 257–258, 261–262, 269, 280; propensity score and, 258–259, 266–270, 273–282, 284, 377, 392, 399, 491, 494; pseudo-outcomes and, 480–485, 487, 490–493, 495; randomization distribution and, 273; randomized experiments and, 257, 259, 264, 267, 270–275, 279; random variables and, 271; regression analysis and, 263, 272–274, 276–277, 280, 494; regular assignment mechanisms and, 258–266, 276, 279, 479; robustness and, 260, 270, 274–277, 481–482, 487–490, 494–495; samples and, 257–262, 268–279, 490–494, 497–499, 501–502, 505, 508–509; sampling variances and, 268–270, 437, 445; sensitivity analysis and, 279, 496–500, 503–504, 506–507, 509; standard deviation and, 277; stratified randomized experiments and, 259, 275, 279; strongly ignorable treatment assignment and, 39; subclassification and, 270, 273–276, 490, 494; subpopulations and, 257, 259, 262, 270, 277–278, 482, 485, 487, 489, 493t–494t; subsamples and, 257–259, 276–277, 493; subset, 480–483, 487–490, 494; super-populations and, 260–261, 263, 266–273, 277, 479, 482, 488–489; supporting analysis and, 479, 495; testability of, 261–262; trimming and, 361; weighting and, 270, 273–275
- unit assignment probability, 34
- University of California, xvii
- Vietnam War, 543
- vitamin supplements, 516–517, 520–521, 528, 538–541
- weighting: average treatment effect and, 441–445; general causal estimands and, 462; Horvitz-Thompson, 282, 378, 379t, 392–400, 443; labor market and, 246; lotteries and, 443–445; matching and, 343, 432; propensity score and, 270, 273–275, 281–282, 378, 392–399; sampling variances and, 441–445; stratified randomized experiments and, 194; unconfoundedness and, 270, 273–275
- Wilcoxon rank sum test, 67, 82
- wishart distribution, 209
- z-values, 298–303, 304t–305t, 306f, 321